公开(公告)号：US20220257656A1

公开(公告)日：2022-08-18

申请号：US17625442

申请日：2020-07-09

申请人： National Cancer Center ,  Kotai Biotechnologies, Inc.

发明人： Yosuke Togashi ,  Hiroyoshi Nishikawa ,  Kazuo Yamashita ,  Nicolas Claude Paul Sax

IPC分类号： A61K35/17 ,  A61K35/545 ,  C12N5/0783

摘要： The present disclosure provides a specific marker for identifying T cells specifically attacking cancer cells and the utilization of the marker. According to the present disclosure, a marker that has a high specificity for identifying T cells specifically attacking cancer cells is provided. According to the present disclosure, treatment or prevention of cancer in a subject with the use of a cell subpopulation contained in a tumor tissue infiltrating CD106+ T cell population or cells expressing a T cell receptor (TCR) expressed thereby can be provided. According to another embodiment of the present disclosure, a method for producing a cellular medicine can be provided. According to the present disclosure, further, a method that comprises using the amount of a cell subpopulation as an index of the responsiveness of a subject to a cancer immunotherapy can be provided. According to the present disclosure, furthermore, a method for acquiring a tumor specific TCR sequence can be provided.

公开(公告)号：US20240052309A1

公开(公告)日：2024-02-15

申请号：US18259687

申请日：2021-12-29

申请人： THYAS CO. LTD. ,  KOTAI BIOTECHNOLOGIES, INC.

发明人： Shin Kaneko ,  Ryosuke Gonotsubo ,  Mitsujiro Osawa ,  Yasumichi Hitoshi ,  Kazuo Yamashita ,  Nicolas Claude Paul Sax

IPC分类号： C12N5/0783 ,  A61P35/00 ,  C07K14/725 ,  C12N9/22 ,  A01N1/02

CPC分类号： C12N5/0636 ,  A61P35/00 ,  C07K14/7051 ,  C12N9/22 ,  A01N1/0284 ,  C12N2506/45 ,  C12N2310/20 ,  C12N2506/115

摘要： [Problems]
To provide a method for producing regenerated T cells via iPS cells into which TCRs isolated from tumor tissue-infiltrating CD106-positive T cells have been introduced.
[Solutions]
Provided is a method for producing regenerated T cells via iPS cells, comprising: 1. A step for preparing cDNAs respectively encoding a TCR α chain and a TCR β chain from individual cells in a CD106-positive T cell population obtained from subjects and having reactivity with a tumor-related antigen; 2. A step for reprogramming peripheral blood mononuclear cells which are obtained from the subjects and from which B cells and T cells have been removed or T cells into iPS cells, and selecting iPS cell clones having high efficiency of differentiation into T cells from the obtained iPS cells; 3. A step for introducing the cDNAs into the iPS cell clones, hematopoietic stem cells differentiated from the iPS cell clones, immature T cells differentiated from the hematopoietic stem cells, or mature T cells differentiated from the immature T cells; and 4. A step for performing the differentiation of the iPS cell clones having the cDNAs introduced therein, the hematopoietic stem cells or the immature T cells which have been obtained in step 3 into mature T cells and the proliferation of the mature T cells.

公开(公告)号：US20240309051A1

公开(公告)日：2024-09-19

申请号：US18282385

申请日：2022-03-15

申请人： OSAKA UNIVERSITY ,  KOTAI Biotechnologies, Inc.

发明人： Sho Yamasaki ,  Xiuyuan Lu ,  Yuki Hosono ,  Shigenari Ishizuka ,  Kazuo Yamashita ,  Nicolas Claude Paul Sax

IPC分类号： C07K14/005 ,  A61K38/00 ,  A61K39/00 ,  C07K16/28

CPC分类号： C07K14/005 ,  C07K16/2809 ,  A61K38/00 ,  A61K2039/572 ,  C12N2770/20022 ,  C12N2770/20034

摘要： Follicular helper T cells specific to SARS-COV-2 virus are provided. The present disclosure is based on the finding of public TfhTCR specific to spike (S) protein common to various patients, and has identified for the first time a public TCR specific to the SARS-COV-2 virus and its MHC and antigenic epitopes to promote efficient immune responses, particularly those of B cells that produce neutralizing antibodies. For example, the present disclosure provides a composition containing an epitope specific to SARS-COV-2 virus for inducing a follicular T cell.

公开(公告)号：US20240159738A1

公开(公告)日：2024-05-16

申请号：US18282411

申请日：2022-03-15

申请人： OSAKA UNIVERSITY ,  KOTAI Biotechnologies, Inc.

发明人： Sho Yamasaki ,  Xiuyuan Lu ,  Yuki Hosono ,  Shigenari Ishizuka ,  Kazuo Yamashita ,  Nicolas Claude Paul Sax

IPC分类号： G01N33/50 ,  G16H10/60 ,  G16H20/10 ,  G16H50/20

CPC分类号： G01N33/505 ,  G16H10/60 ,  G16H20/10 ,  G16H50/20 ,  G01N2800/50 ,  G01N2800/52

摘要： A new medical technique using follicular T cells is provided. The present disclosure is based on the finding of public TfhTCR which is specific to disease factors common to various patients, and provides a method for producing follicular T cells specific to a disease, including a step of identifying a disease-related factor or a part thereof having the ability to induce a follicular T cell reactive with the disease-related factor, a step of inducing the follicular T cell specific to the disease, by using the disease-related factor or a part thereof, and a step of obtaining the follicular T cell specific to the disease.

公开(公告)号：US20210012858A1

公开(公告)日：2021-01-14

申请号：US16981629

申请日：2019-03-15

申请人： KOTAI Biotechnologies, Inc.

发明人： Kazuo Yamashita ,  Joel Billaud ,  Nicolas Claude Paul Sax

IPC分类号： G16B15/20 ,  G01N33/53 ,  G16B30/10 ,  G16B45/00

摘要： The present invention provides a method for classifying immunological entities. The inventors assume that there are commonalities among antigen specificities for which, without a function being specified in advance, bound immunological entities (antigens, epitopes, etc.) are normally handled individually as separate “functions (for example, whether antigen A has the specificity),” and the inventors have discovered that it is possible to classify immunological entities by evaluating the similarities thereof. This method has a high degree of precision with respect to immunity-related illnesses, and the present invention is clinically applicable.